Skip to main content

Table 3 Rates of patients’ preferencea (mITT/ITT/PP population)

From: Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

mITTArm A (N = 5)Arm B (N = 8)Total (N = 13)
n (%)95%-CIn (%)95%-CIn (%)95%-CI
Cap+Bev2 (40.0%)[5.3, 85.3]6 (75.0%)[34.9, 96.8]8 (61.5%)[31.6, 86.1]
Eve+Exe1 (20.0%)[0.5, 71.6]1 (12.5%)[0.3, 52.7]2 (15.4%)[1.9, 45.4]
I cannot decide2 (40.0%)[5.3, 85.3]1 (12.5%)[0.3, 52.7]3 (23.1%)[5.0, 53.8]
p-value (Chi-square)    0.1653 
ITTArm A (N = 39)Arm B (N = 38)Total (N = 77)
n (%)95%-CIn (%)95%-CIn (%)95%-CI
Cap+Bev3 (7.7%)[1.6, 20.9]10 (26.3%)[13.4, 43.1]13 (16.9%)[9.3, 27.1]
Eve+Exe5 (12.8%)[4.3, 27.4]2 (5.3%)[0.6, 17.7]7 (9.1%)[3.7, 17.8]
I cannot decide3 (7.7%)[1.6, 20.9]4 (10.5%)[2.9, 24.8]7 (9.1%)[3.7, 17.8]
Not evaluable2 (5.1%)[0.6, 17.3]2 (5.3%)[0.6, 17.7]4 (5.2%)[1.4, 12.8]
Item / questionnaire not answered4 (10.3%)[2.9, 24.2]1 (2.6%)[0.1, 13.8]5 (6.5%)[2.1, 14.5]
No second-line therapy22 (56.4%)[39.6, 72.2]19 (50.0%)[33.4, 66.6]41 (53.2%)[41.5, 64.7]
PPArm A (N = 13)Arm B (N = 18)Total (N = 31)
n (%)95%-CIn (%)95%-CIn (%)95%-CI
Cap+Bev3 (23.1%)[5.0, 53.8]10 (55.6%)[30.8, 78.5]13 (41.9%)[24.5, 60.9]
Eve+Exe5 (38.5%)[13.9, 68.4]2 (11.1%)[1.4, 34.7]7 (22.6%)[9.6, 41.1]
I cannot decide3 (23.1%)[5.0, 53.8]4 (22.2%)[6.4, 47.6]7 (22.6%)[9.6, 41.1]
Not evaluable2 (15.4%)[1.9, 45.4]2 (11.1%)[1.4, 34.7]4 (12.9%)[3.6, 29.8]
  1. aPatient’s treatment preference was evaluated after 12 weeks of second-line treatment, assessed by the Patient Preference Questionnaire. Confidence interval was calculated using the Clopper-Pearson formula. Due to small n, the p-value of the asymptotic chi-square test may not be valid. The p-value of the corresponding exact test was 0.1666. Not evaluable: Patients selected more than one possible answer. mITT = modified ITT; ITT = intent-to-treat; PP = per-protocol; CI = confidence interval
\